Can a THC-Based drug calm Alzheimer's agitation? new trial aims to find out
NCT ID NCT07422311
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether dronabinol, a synthetic form of THC (the active ingredient in cannabis), can safely reduce agitation in people with Alzheimer's disease. About 140 adults aged 50 to 90 with Alzheimer's-related agitation will receive either dronabinol or a placebo for 12 weeks, followed by a 6-month extension where everyone gets the active drug. The goal is to see if the drug improves agitation scores compared to placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dronabinol oral solution (a synthetic form of THC, the active ingredient in cannabis)
What this could lead to
If it works, this could provide a new option to reduce agitation in people with Alzheimer's, improving their quality of life and easing caregiver burden.
What could go wrong
This is an early-to-mid-stage trial with only 140 participants. Dronabinol may not work better than placebo, and side effects like dizziness or confusion are possible, especially in older adults.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Finders Medical Center
Bedford Park, SA Adelaide, 5042, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact